Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates

Biotechnology Journal

Volumn 7, Issue 12, 2012, Pages 1444-1450

  Vincent, Karen J ^a   Zurini, Mauro ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antibody; Bioengineering; Biopharmaceuticals; Clinical application; Technologies

Indexed keywords

ANTIBODY DRUGS; ANTIBODY ENGINEERING; ANTIGEN BINDING; BIOPHARMACEUTICALS; CLINICAL APPLICATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CYTOTOXIC; FC REGION; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODIES (MABS); PH-DEPENDENT; TARGET MOLECULE; THERAPEUTIC ANTIBODIES;

ANTIBODIES; ANTIGENS; MEDICAL APPLICATIONS; MOLECULES; MONOCLONAL ANTIBODIES; SYSTEMS SCIENCE; TECHNOLOGY;

ENGINEERING;

ANTIBODY; BETA GLUCURONIDASE; BETA SECRETASE 1; BISPECIFIC ANTIBODY; CD20 ANTIBODY; DRUG ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; N ACETYLGLUCOSAMINYLTRANSFERASE; OBINUTUZUMAB; TOSITUMOMAB I 131;

ALGORITHM; ANTIBODY ENGINEERING; ANTIGEN BINDING; BLOOD BRAIN BARRIER; CONJUGATE; CYTOTOXICITY; DRUG INDUSTRY; HUMAN; NONHUMAN; PH; PHAGOCYTOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN INTERACTION; PROTEIN MODIFICATION; SHORT SURVEY;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY AFFINITY; DRUG DELIVERY SYSTEMS; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOCONJUGATES; PROTEIN BINDING; PROTEIN ENGINEERING; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS;

EID: 84870680776     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201200250     Document Type: Short Survey

References (38)

1. Lazar, G. A., Dang, W., Karki, S., Vafa, O. et al., Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. USA 2006, 103, 4005-4010.
2. Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G. et al., High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J. Biol. Chem. 2001, 276, 6591-6604.
3. Stavenhagen, J. B., Gorlatov, S., Tuaillon, N., Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fc? receptors. Cancer Res. 2007, 67, 8882-8890.
4. Moessner, E., Bruenker, P., Moser, S., Puentener, U. et al., Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010, 115, 4393-4402.
5. Ishida, T., Joh, T., Uike, N., Yamamoto, K. et al., Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter Phase II study. J. Clin. Oncol. 2012, 10, 837-842.
6. Matsushita, T., Engineered therapeutic antibodies with enhanced effector functions: Clinical application of the Potelligent® Technology. Korean J. Hematol. 2011, 46, 148-150.
7. Xu, D., Alegre, M., Varga, A. S., Rothermel, A. L. et al., In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol. 2000, 200, 16-26.
8. Lund, J., Takahashi, N., Pound, J. D., Goodall, M. et al., Oligosaccharide-protein interactions in IgG can modulate recognition by Fcγ receptors. FASEB J. 1995, 9, 115-119.
9. Moore, G. L., Chen, H., Karki, S., Lazar, G. A. et al., Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2010, 2, 181-189.
10. Idusogie, E. E., Wong, P. Y., Presta, L. G., Gazzano-Santoro, H. et al., Engineered antibodies with increased activity to recruit complement. J. Immunol. 2001, 166, 2571-2575.
11. Idusogie, E. E., Presta, L. G., Gazzano-Santoro, H., Totpal, K. et al., Mapping of the C1q binding site on Rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 2000, 164, 4178-4184.
12. Dall'Acqua, W., Kiener, P. A., Wu, H., Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem. 2006, 281, 23514-23524.
13. Zalevsky, J., Chamberlain, A. K., Horton, H. M., Karki, S. et al., Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol. 2010, 28, 157-159.
14. Igawa, T., Ishii, S., Tachibana, T., Maeda, A. et al., Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat. Biotechnol. 2010, 28, 1203-1207.
15. Chaparro-Riggers, J., Liang, H., DeVay, R. M., Bai, L. et al., Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J. Biol. Chem. 2012, 287, 11090-11097.
16. Marvin, J. S., Zhu, Z., Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol. Sin. 2005, 26, 649-658.
17. Ridgway, J. B., Presta, L. G., Carter, P., 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 1996, 9, 617-621.
18. Atwell, S., Ridgway, J. B., Wells, J. A., Carter, P. et al., Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J. Mol. Biol. 1997, 270, 26-35.
19. Carter, P., Bispecific human IgG by design. J. Immunol. Methods 2001, 248, 7-15.
20. Vassar, R., Bennett, S., Babu-Khan, S., Kahn, S. et al., β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286, 735-741.
21. Roberds, S. L., Anderson, J., Basi, G., Bienkowski, M. J. et al., BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: Implications for alzheimer's disease therapeutics. Hum. Mol. Genet. 2001, 10, 1317-1324.
22. Fishman, J. B., Rubin, J. B., Handrahan, J. V., Connor, J. R. et al., Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J. Neurosci. Res. 1987, 18, 299-304.
23. Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K. et al., Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Transl. Med. 2011, 3, 84ra44.
24. Schaefer, W., Regula, J. T., Baehner, M., Schanzer, J. et al., Immunoglobulin domain crossover as a generic approach for the production of bispecifics IgG antibodies. Proc. Natl. Acad. Sci. USA 2011, 108, 11187-11192.
25. Gunasekaran, K., Pentony, M., Shen, M., Enhancing antibody Fc heterodimer formation through electrostatic steering effects: Applications to bispecific molecules and monovalent IgG. J. Biol. Chem. 2010, 285, 19637-19646.
26. Bostrom, J., Yu, S., Kan, D., Appleton, B. A. et al., Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009, 323, 1610-1614.
27. Labrijin, A. F., Rispens, T., Meesters, J., Rose, R. J. et al., Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength. J. Immunol. 2011, 187, 3238-3246.
28. Conner, S. D., Schmid, S. L., Regulated portals of entry into the cell. Nature 2003, 422, 37-44.
29. Erickson, H. K., Park, P. U., Widdison, W. C., Kovtun, Y. V. et al., Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006, 66, 4426-4433.
30. Dubowchik, G. M., Firestone, R. A., Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg. Med. Chem. Lett. 1998, 8, 3341-3346.
31. Jeffrey, S. C., Nguyen, M. T., Moser, R. F., Meyer, D. L. et al., Minor groove binder antibody conjugates employing a water soluble beta-glucuronide linker. Bioorg. Med. Chem. Lett. 2007, 17, 2278-2280.
32. Okeley, N. M., Miyamoto, J. B., Zhang, X., Sanderson, R. J. et al., Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin. Cancer Res. 2010, 16, 888-897.
33. Isakoff, S. J., Baselga, J., Trastuzumab-DM1: Building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 2011, 29, 351-354.
34. 131I-tositumomab in clinical practice. J. Nucl. Med. 2007, 48, 1767-1776.
35. Holmes, D., Buy buy bispecific antibodies. Nat. Rev. Drug Discov. 2011, 10, 798-800.
36. Schrama, D., Reisfeld, R. A., Becker, J. C., Antibody targeted drugs as cancer therapeutics. Nat. Rev. Drug Discov. 2006, 5, 147-159.
37. Beck, A., Haeuw, J., Wurch, T., Goetsch, L. et al., The next generation of antibody-drug conjugates comes of age. Discov. Med. 2010, 10, 329-339.
38. Kontermann, R., Duebel, S. (Eds.), Antibody engineering, Springer, 2010.